Article

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than <i>TP53</i> mutation status

2020-11-29

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Purpose</h4> APR-246 (Eprenetapopt) is in clinical development with a focus on haematological malignancies and is marketed as a mutant-p53 reactivation therapy. Currently, the detection of at least one TP53 mutation is an inclusion criterion for patient selection into most clinical trials. Preliminary results from our phase Ib/II clinical trial investigating APR-246 combined with combinati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 37068b0f-8b79-5dbe-a3f8-fae3093b443d
DOI: 10.1101/2020.11.29.398875

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than <i>TP53</i> mutation statusDOI 10.1101/2020.11.29.398875Read

SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status.Semantic proximity Read

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.Semantic proximity Read

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsSemantic proximity Read

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.Semantic proximity Read

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer TherapySemantic proximity Read

APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer.Semantic proximity Read

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.Semantic proximity Read

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies.Semantic proximity Read

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read

Mutant p53 as a target for cancer treatment.Semantic proximity Read

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsSemantic proximity Read